These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28748450)

  • 1. Replicating Health Economic Models: Firm Foundations or a House of Cards?
    Bermejo I; Tappenden P; Youn JH
    Pharmacoeconomics; 2017 Nov; 35(11):1113-1121. PubMed ID: 28748450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success.
    Schwander B; Nuijten M; Evers S; Hiligsmann M
    Pharmacoeconomics; 2021 Apr; 39(4):433-446. PubMed ID: 33751452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers and Facilitators to Model Replication Within Health Economics.
    McManus E; Turner D; Gray E; Khawar H; Okoli T; Sach T
    Value Health; 2019 Sep; 22(9):1018-1025. PubMed ID: 31511178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.
    de Boer PT; Frederix GW; Feenstra TL; Vemer P
    Pharmacoeconomics; 2016 Sep; 34(9):833-45. PubMed ID: 27129572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.
    Chetty M; Kenworthy JJ; Langham S; Walker A; Dunlop WC
    Addict Sci Clin Pract; 2017 Feb; 12(1):6. PubMed ID: 28235415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath.
    Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R
    Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the credibility of health economic models for health policy decision-making: a systematic literature review of screening for abdominal aortic aneurysms.
    Søgaard R; Lindholt J
    J Health Serv Res Policy; 2012 Jan; 17(1):44-52. PubMed ID: 21954237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of decision analytic modeling in the health economic assessment of spinal intervention.
    Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological and conceptual issues regarding occupational psychosocial coronary heart disease epidemiology.
    Burr H; Formazin M; Pohrt A
    Scand J Work Environ Health; 2016 May; 42(3):251-5. PubMed ID: 26960179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
    Cooper NJ; Sutton AJ; Abrams KR
    Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoiding and identifying errors and other threats to the credibility of health economic models.
    Tappenden P; Chilcott JB
    Pharmacoeconomics; 2014 Oct; 32(10):967-79. PubMed ID: 25027943
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.